Hisamitsu Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Kazue Nakatomi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 11yrs |
Recent management updates
Recent updates
We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings
Apr 18
With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case
Mar 07Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?
Feb 17Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00
Jan 13Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00
Dec 30Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 27Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing
Sep 16Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 20Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00
Jul 26Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 11Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00
Jun 27Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00
Jun 13Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price
Apr 09Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching
Mar 18CEO
Kazue Nakatomi (52 yo)
Mr. Kazuhide Nakatomi, also known as Kazue, serves as Chief Executive Officer since May 2019, President since May 2015 & Director since May 2007 at Hisamitsu Pharmaceutical Co. Inc. and served as its Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10yrs | no data | 0.34% ¥ 1.0b | |
| Executive VP & Head of Global Technology | 1.3yrs | no data | no data | |
| Exe Officer of Legal Affairs | 11yrs | no data | 0.0069% ¥ 20.8m | |
| Executive MD of Human Resources | 1.3yrs | no data | 0.018% ¥ 54.0m | |
| Senior Managing Executive Officer | 1.3yrs | no data | no data | |
| MD, Executive Officer | no data | no data | 0.0096% ¥ 29.1m | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | no data | no data | 0.0082% ¥ 24.9m | |
| Senior Executive Officer & GM of Pharmaceutical Business Division | no data | no data | no data | |
| Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Division | no data | no data | no data | |
| Executive Officer | 4yrs | no data | 0.0041% ¥ 12.5m | |
| Senior Executive Officer & GM of MN Business Promotion Office | 2.3yrs | no data | no data | |
| Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Division | 1.3yrs | no data | no data |
Experienced Management: 4530's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18yrs | no data | 0.34% ¥ 1.0b | |
| Exe Officer of Legal Affairs | 11yrs | no data | 0.0069% ¥ 20.8m | |
| Executive MD of Human Resources | 26yrs | no data | 0.018% ¥ 54.0m | |
| MD, Executive Officer | 12yrs | no data | 0.0096% ¥ 29.1m | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | 11yrs | no data | 0.0082% ¥ 24.9m | |
| Executive Officer | 4yrs | no data | 0.0041% ¥ 12.5m | |
| Standing Corporate Auditor | 19yrs | no data | 0.0027% ¥ 8.3m | |
| Part-time Outside Independent Director | 5yrs | no data | 0.0014% ¥ 4.2m | |
| Part-time Outside Independent Director | 5yrs | no data | no data | |
| Part Time Outside Corporate Auditor | 2yrs | no data | no data | |
| Part Time Outside Independent Director | 2yrs | no data | no data |
Experienced Board: 4530's board of directors are seasoned and experienced ( 11 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 02:29 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/02/28 |
| Annual Earnings | 2025/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |